The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
A phase 1/2 trial of durvalumab and regorafenib in gallbladder cancer and other biliary tract cancers, run by University of Kansas Medical Center, active and no longer recruiting.
Overview
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers is a phase 1/2 interventional study registered as NCT04781192 by University of Kansas Medical Center, with a registry enrolment figure of 40 participants, started 2022-03-22 and due to reach its primary completion in 2025-11-12. Interventions recorded: Durvalumab, Regorafenib. Conditions listed: Advanced Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "* Histologically confirmed unresectable or metastatic intrahepatic/extrahepatic cholangiocarcinoma or gallbladder cancer with radiographic progression, who have progressed on one line of therapy / failed adjuvant therapy". Sites: United States. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
- TrialA Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
- TrialOlaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
- TrialHAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialKN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialThe Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialImmunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.